SINGAPORE, April 24, 2025 /PRNewswire/ — Cloud4C, world’s leading multi-cloud MSP and a trusted AI transformation partner, announces its partnership with ORIX Rentec Corporation (“ORIX Rentec”), a group company of ORIX, which is a diversified multinational financial services group, to render GPU Cloud services in Japan.

Cloud4C will deliver a security-first GPU cloud wherein enterprises can access hyperscale performant GPU clusters on-demand to operate their AI workloads. The cloud will be available in private, hybrid cloud mode allowing integration with a firm’s existing landscapes. Unifying operational platforms, technologies, and managed services from dedicated COEs, the offering empowers businesses with a risk-proof sovereign AI stack. The service starts in 2025 helping institutions accelerate their AI, R&D, and product initiatives.

“This is a landmark engagement for us in Japan, a global innovation hub and key region for Cloud4C. Combining our world-class GPU infrastructure, managed cloud, and AI capabilities with ORIX Rentec’s diversified industrial expertise will bolster adoption of AI’s breakthrough potential across sectors,” mentioned Sridhar Pinnapureddy, Chairman and Managing Director, Cloud4C.

Chanakya Levaka, COO, Cloud4C said, “Unlocking the real value of AI requires affordable accelerated compute, precise operational stacks, security-first and sovereign frameworks, and above all skilled resources. Partnering with ORIX Rentec, we aim to deliver a GPU cloud that is engineered for impactful AI outcomes risk-proof, maximizing ROI.”

Toshiyuki Okino, Managing Executive Officer, ORIX Rentec Corporation mentions, “ORIX Rentec is very happy to provide this service as a partner with Cloud4C. Cloud4C’s high-quality, security-first GPU cloud ecosystem will accelerate AI adoption and research & development in Japan. We believe it will also drive demand for rentals and service usage of edge devices such as electronic measuring instruments, IT equipment, robots, drones, and 3D printers, as well as the manufacturers of these devices. As these are our core products and target customer base, we are confident that this partnership will provide new services and value to companies advancing AI and DX, contributing to their business transformation.”

About Cloud4C

Cloud4C is a global leader in AI-driven Managed Services and Security services, enabling 4,000+ enterprises across 29 countries to adopt AI and drive secure, intelligent, and scalable cloud transformations. Backed by a 99.95% uptime SLA from infrastructure to application login, we empower agility through automation, predictive analytics, and industry-specific, security-rich architectures.

~ Adopted by Leading Industry Players, with 66% Share in Banking and 96% in Telecommunications ~

TOKYO, April 24, 2025 /PRNewswire/ — Liquid Inc., a member of the ELEMENTS Group, is pleased to announce that “LIQUID eKYC,” has achieved the No.1 market share for the sixth consecutive year in vendor revenue share within the eKYC market. This recognition comes from the market research report “ITR Market View: Identity & Access Management / Personal Authentication Security Market 2025” published by ITR Corporation (Head Office: Shinjuku-ku, Tokyo; President: Motohiro Miura).

Background
Since 2019, the ELEMENTS Group has been offering the online identity verification service “LIQUID eKYC” as one of its personal authentication solutions. The service supports a variety of verification methods, including capturing images of identification documents such as driver’s licenses and My Number cards, reading data from IC chips, and matching them with a selfie, as well as utilizing public personal authentication methods (JPKI / smartphone JPKI). These capabilities have enabled the company to meet identity verification needs across a wide range of industries. In March 2025, ELEMENTS Group acquired Polarify as a subsidiary and now also provides the “Polarify eKYC” service, which, like “LIQUID eKYC,” enables online identity (and background) verification.

About Market Share

No.1 Market Share for 6 Consecutive Years^※, with Approximately 130 Million Cumulative Identity Verifications and Around 600 Client Companies

Our online identity verification service, LIQUID eKYC, has been increasingly adopted across various industries due to its low user drop-off rate enabled by highly accurate facial recognition and image processing technologies, along with its advanced IC solutions designed to anticipate future legal and regulatory changes. As a result, it has maintained the No.1 market share for six consecutive years. ^※

Including Polarify eKYC, the ELEMENTS Group has achieved approximately 130 million cumulative identity verification transactions and has contracts with about 600 companies in total.

By Industry: 66% Share in Banking and 96% in Telecommunications (According to Our Research)

In the banking sector, 66% of banks that have implemented eKYC have adopted the ELEMENTS Group’s online identity verification services. In the telecommunications sector, 3 out of the 4 major mobile carriers in Japan are using our solutions, representing a 96% share based on the number of contracts. This demonstrates the strong trust we have earned in industries where identity verification is mandated by laws such as the Act on Prevention of Transfer of Criminal Proceeds and the Act on Prevention of Improper Use of Mobile Phones.

About LIQUID eKYC: No.1 Market Share for Six Consecutive Years^※
The service provides online completion of identity verification required for online contracts, account registration, and account opening. We offer a method that takes a picture of an identification document or reads an IC chip and matches it with selfies, as well as a method that utilizes public personal authentication (JPKI / Smartphone JPKI). We can also support age verification for student discounts. Our proprietary AI, biometric, and OCR technologies have enabled us to maintain a low drop-off rate from the start to the end of the photo shooting process. As a result, the ELEMENTS Group has achieved a cumulative total of approximately 130 million identity verifications, with around 600 companies having adopted our services.
Website: https://liquidinc.asia/global/kyc-application/

※ITR “ITR Market View: Identity Access Management / Personal Authentication Type Security Market 2025 eKYC Market: Sales Value Share by Vendor (FY2019-FY2024Forecast)

About Liquid Inc.
Liquid aims to create a seamless world where all of the world’s approximately 8 billion people can easily and safely use all services as they are, by automatic and ubiquitous authentication. We provide our own Digital ID, KYC, and Authentication service, where users can prove their identity anytime, anywhere in the world with their smartphone or face. We are expanding our service globally and use the know-how accumulated under the strict Japanese laws and rules. We adapt our operations and services flexibly and quickly to changes in the required legal and security framework.
For more information, visit: https://liquidinc.asia/global/

SAN FRANCISCO and SUZHOU,China, April 24, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that clinical data for its innovative bispecific antibodies and ADC molecules, including oral presentations for IBI363 (PD-1/IL-2^α-bias) and IBI343 (CLDN18.2 ADC), will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 from May 30 to June 3, 2024, in Chicago, Illinois, U.S.

Dr. Hui Zhou, Senior Vice President of Innovent, stated: “We are delighted to announce that at 2025 ASCO Annual Meeting, the first wave of three indications under development for IBI363—melanoma, colorectal cancer(CRC), and non-small cell lung cancer (NSCLC)—have all been accepted for oral presentations, highlighting the significant attention garnered by the next-generation bispecific antibodies, in particular PD-1-based immunotherapy. Additionally, following its oral presentation at ESMO Asia last December, the Phase 1b data of IBI343 in pancreatic cancer has once again secured an oral presentation at ASCO, further solidifying its potential in this challenging therapeutic area. The maturing PoC data for these innovative candidates has strengthened our confidence in advancing them into pivotal-stage development, with the goal of unlocking their clinical value for global unmet clinical needs. As one of the few biopharmaceutical companies with both the advanced technology platforms and robust pipeline in “IO+ADC” areas, Innovent will continue to make breakthroughs in the field of cancer treatment, and is committed to providing physicians and patients with more innovative, effective and safe treatment options.”

Details on the abstracts are listed below:

Oral Presentation

1. Presentation Title: Efficacy and safety results of a first-in-class PD-1/IL-2^α-bias bispecific antibody fusion protein, IBI363, in patients with immunotherapy-treated, advanced acral and mucosal melanoma

Abstract Number: 2502
Session Type: Oral Abstract
Session Title: Developmental Therapeutics-Immunotherapy
Session Date & Time: 5/31/2025 3:00 PM-6:00 PM CDT
Presenter: Jun Guo, MD, Beijing Cancer Hospital

2. Presentation Title: Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab in patients with advanced colorectal cancer

Abstract Number: 104
Session Type: Oral Abstract
Session Title: Clinical Science Symposium—Turning “Cold” Tumors “Hot”
Session Date & Time: 6/1/2025 9:45 AM-11:15 AM CDT
Presenter: Zhenyu Lin, MD, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

3. Presentation Title: First-in-class PD-1/IL-2^α-bias bispecific antibody, IBI363, in patients with advanced immunotherapy-treated non-small cell lung cancer (NSCLC)

Abstract Number: 8509
Session Type: Oral Abstract
Session Title: Clinical Science Symposium—Two Targets, One Goal: The Potential for Bispecific Antibodies in Thoracic Malignancies
Session Date & Time: 6/3/2025 9:45 AM-11:15 AM CDT
Presenter: Jianya Zhou, MD, The First Affiliated Hospital, Zhejiang University School of Medicine

4. Presentation Title: Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): results from a Phase 1 dose expansion cohort evaluating IBI343

Abstract Number: 4017
Session Type: Rapid Oral Abstract
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date & Time: 6/2/2025 11:30 AM-1:00 PM CDT
Presenter: Xianjun Yu, MD, Fudan University Shanghai Cancer Center

5. Presentation Title: Sintilimab (anti-PD-1) plus ifosfamide, carboplatin and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind Phase 3 study (ORIENT-21)

Abstract Number: 7007
Session Type: Oral Abstract
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Session Date & Time: 5/30/2025 2:45 PM-5:45 PM CDT
Presenter: Peng Liu,MD, Cancer Hospital, Chinese Academy of Medical Sciences

6. Presentation Title: Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: A prospective, randomized controlled trial (SPRING-01)

Abstract Number: 3519
Session Type: Rapid Oral Abstract
Session Title: Gastrointestinal Cancer-Colorectal and Anal
Session Date & Time: 6/1/2025 11:30 AM-1:00 PM CDT
Presenter：Changqing Jing, MD, Shandong Provincial Hospital

7. Presentation Title: Dynamic circulating tumor DNA-driven, risk-adapted systematic therapy in nasopharyngeal carcinoma: The EP-STAR trial

Abstract Number: 6010
Session Type: Oral Abstract
Session Title: Clinical Science Symposium -Biomarker-Driven Adaptive Therapy: New Horizons in Head and Neck Cancer
Session Date & Time: 6/2/2025 3:00 PM-4:30 PM CDT
Presenter: Ying Sun, MD, Sun Yat-sen University Cancer Center

Poster Presentation

1. Presentation Title: A multicenter, randomized, controlled, open-label, Phase 2 study of the PD-1/IL-2^α-bias bispecific antibody fusion protein IBI363 in mucosal and acral melanoma: Trial in Progress

Abstract Number: TPS9594
Session Type: Poster
Session Title: Melanoma/Skin Cancers
Session Date & Time: 6/1/2025 9:00 AM-12:00 PM CDT
Presenter: Bin Lian, MD, Peking University Cancer Hospital & Institute

2. Presentation Title: IBI354, an anti-HER2 antibody-drug conjugate, in patients with locally advanced unresectable or metastatic ovarian cancers: updated results from a Phase 1 trial

Abstract Number: 5565
Session Type: Poster
Session Title: Gynecologic Cancer
Session Date & Time: 6/1/2025 9:00 AM-12:00 PM CDT
Presenter: Jin Shu, MD, Chongqing University Cancer Hospital

3. Presentation Title: IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients with HER2-positive breast cancer (BC) and other solid tumors: Updates from a Phase 1 study

Abstract Number: 1029
Session Type: Poster
Session Title: Breast Cancer—Metastatic
Session Date & Time: 6/2/2025 9:00 AM-12:00 PM CDT
Presenter: Charlotte Rose Lemech, BSc, FRACP, MBBS , Scientia Clinical Research

4. Presentation Title: Safety and efficacy of the anti-TROP2 antibody-drug conjugate (ADC) IBI130 in patients with advanced triple-negative breast cancer (TNBC) and other solid tumors: Results from the Phase 1 study

Abstract Number: 1102
Session Type: Poster
Session Title: Breast Cancer—Metastatic
Session Date & Time: 6/2/2025 9:00 AM-12:00 PM CDT
Presenter: Fan Wu, MD, Fujian Cancer Hospital

5. Presentation Title: A multiregional, randomized, controlled, open-label, Phase 3 study of the anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) arcotatug tavatecan (IBI343) in gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Trial in Progress

Abstract Number: TPS4201
Session Type: Poster
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date & Time: 5/31/2025 9:00 AM-12:00 PM CDT
Presenter: Lin Shen, MD, Beijing Cancer Hospital

6. Presentation Title: Phase 2 trial of transarterial chemoembolization followed by sintilimab (anti-PD-1), oxaliplatin, and S-1 combined with either trastuzumab (HER-2 positive) or apatinib (HER-2 negative) as first-line therapy for gastric cancer with liver metastases.

Abstract Number: 4050
Session Type: Poster
Session Title: Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date & Time: 5/31/2025 9:00 AM-12:00 PM CDT
Presenter: Dan Sha, MD, Shandong Provincial Hospital

*Abstracts of TYVYT ^®(sintilimab) are from investigator-initiated clinical trials (IIT), except one abstract, #7007.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

(1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).

(2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent Biologics (“Innovent”), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.